Physician profile
David James Weis
NPI 1770576290
$820.88
in general payments reported to CMS, 2019-2025
11 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.16 · 2020: $24.18 · 2023: $152 · 2024: $425 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $294.63 | 2023-2025 | Total30, Wavelight Refractive Suite, Precision7 |
| Abbvie INC. | $123.53 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Astellas Pharma US INC | $93.13 | 2024 | Izervay |
| Harrow Eye, LLC | $90.28 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $89.02 | 2019-2024 | |
| Oyster Point Pharma, INC. | $39.60 | 2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $25.13 | 2025 | Oxervate |
| Amgen INC. | $21.67 | 2024 | Tepezza |
| Thea Pharma INC. | $19.71 | 2025 | Iyuzeh |
| Allergan, INC. | $17.81 | 2020 | |
| Biotissue Holdings INC. | $6.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.